ATE543902T1 - Regulierung von proteinaktivität durch umkehrbare acetylierung - Google Patents
Regulierung von proteinaktivität durch umkehrbare acetylierungInfo
- Publication number
- ATE543902T1 ATE543902T1 AT07809490T AT07809490T ATE543902T1 AT E543902 T1 ATE543902 T1 AT E543902T1 AT 07809490 T AT07809490 T AT 07809490T AT 07809490 T AT07809490 T AT 07809490T AT E543902 T1 ATE543902 T1 AT E543902T1
- Authority
- AT
- Austria
- Prior art keywords
- acecs2
- acetylation
- activity
- sirt3
- lys642
- Prior art date
Links
- 230000021736 acetylation Effects 0.000 title abstract 3
- 238000006640 acetylation reaction Methods 0.000 title abstract 3
- 230000004952 protein activity Effects 0.000 title 1
- 102100030381 Acetyl-coenzyme A synthetase 2-like, mitochondrial Human genes 0.000 abstract 7
- 101710179225 Acetyl-coenzyme A synthetase 2-like, mitochondrial Proteins 0.000 abstract 7
- 108091005770 SIRT3 Proteins 0.000 abstract 3
- 102000000478 Sirtuin 3 Human genes 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- 230000002438 mitochondrial effect Effects 0.000 abstract 2
- 108010049926 Acetate-CoA ligase Proteins 0.000 abstract 1
- 102100035709 Acetyl-coenzyme A synthetase, cytoplasmic Human genes 0.000 abstract 1
- 108060003393 Granulin Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000011990 Sirtuin Human genes 0.000 abstract 1
- 108050002485 Sirtuin Proteins 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000006196 deacetylation Effects 0.000 abstract 1
- 238000003381 deacetylation reaction Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81327506P | 2006-06-12 | 2006-06-12 | |
| US11/761,198 US8518635B2 (en) | 2006-06-12 | 2007-06-11 | Regulation of protein activity by reversible acetylation |
| PCT/US2007/013804 WO2007149270A2 (en) | 2006-06-12 | 2007-06-12 | Regulation of protein activity by reversible acetylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE543902T1 true ATE543902T1 (de) | 2012-02-15 |
Family
ID=38833973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07809490T ATE543902T1 (de) | 2006-06-12 | 2007-06-12 | Regulierung von proteinaktivität durch umkehrbare acetylierung |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8518635B2 (https=) |
| EP (1) | EP2029731B1 (https=) |
| JP (1) | JP2009542195A (https=) |
| AT (1) | ATE543902T1 (https=) |
| AU (1) | AU2007261561B2 (https=) |
| CA (1) | CA2654458A1 (https=) |
| ES (1) | ES2380248T3 (https=) |
| WO (1) | WO2007149270A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| EP2008106A2 (en) | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| HK1213046A1 (zh) | 2012-09-19 | 2016-06-24 | Dana-Farber Cancer Institute, Inc. | 動態bh3分析 |
| CA2922503C (en) | 2013-09-19 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
| AU2016253957C1 (en) | 2015-04-27 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells |
| JP7589159B2 (ja) | 2019-02-26 | 2024-11-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング |
| WO2023122805A1 (en) | 2021-12-20 | 2023-06-29 | Vestaron Corporation | Sorbitol driven selection pressure method |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US82668A (en) * | 1868-09-29 | Thomas b | ||
| US120008A (en) * | 1871-10-17 | Improvement in apparatus for feeding pulverized fuel to metallurgical and other furnaces | ||
| JP2001149081A (ja) | 1999-11-29 | 2001-06-05 | Cyclex Co Ltd | 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法 |
| US20020120008A1 (en) | 2000-06-29 | 2002-08-29 | Seymour Benzer | Life extension of drosophila by a drug treatment |
| US7241743B2 (en) | 2001-06-15 | 2007-07-10 | The Trustees Of Columbia University In The City Of New York | Sir2α-based therapeutic and prophylactic methods |
| US7488587B2 (en) | 2001-06-19 | 2009-02-10 | The J. David Gladstone Institutes | Histone deacetylase and methods of use thereof |
| CA2453195A1 (en) | 2001-07-06 | 2003-01-16 | Leonard Guarente | Sir2 activity |
| US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
| CA2417033A1 (en) | 2003-01-23 | 2004-07-23 | Paul Kerr | External support structure for use in the transporting of manufactured houses |
| US7272713B1 (en) | 2003-10-22 | 2007-09-18 | Symantec Corporation | Controlling file operations |
| US7485416B2 (en) | 2003-12-23 | 2009-02-03 | The Regents Of The University Of California | Screening methods for the identification of agents that inhibit SIRT1 Tat deacetylase activity |
-
2007
- 2007-06-11 US US11/761,198 patent/US8518635B2/en not_active Expired - Fee Related
- 2007-06-12 EP EP07809490A patent/EP2029731B1/en not_active Not-in-force
- 2007-06-12 WO PCT/US2007/013804 patent/WO2007149270A2/en not_active Ceased
- 2007-06-12 CA CA002654458A patent/CA2654458A1/en not_active Abandoned
- 2007-06-12 AU AU2007261561A patent/AU2007261561B2/en not_active Ceased
- 2007-06-12 JP JP2009515460A patent/JP2009542195A/ja active Pending
- 2007-06-12 ES ES07809490T patent/ES2380248T3/es active Active
- 2007-06-12 AT AT07809490T patent/ATE543902T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| US8518635B2 (en) | 2013-08-27 |
| WO2007149270A9 (en) | 2008-03-06 |
| US20090061015A1 (en) | 2009-03-05 |
| EP2029731A4 (en) | 2009-10-21 |
| AU2007261561B2 (en) | 2013-02-28 |
| WO2007149270A2 (en) | 2007-12-27 |
| WO2007149270A3 (en) | 2008-10-30 |
| JP2009542195A (ja) | 2009-12-03 |
| CA2654458A1 (en) | 2007-12-27 |
| EP2029731B1 (en) | 2012-02-01 |
| AU2007261561A1 (en) | 2007-12-27 |
| EP2029731A2 (en) | 2009-03-04 |
| ES2380248T3 (es) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE543902T1 (de) | Regulierung von proteinaktivität durch umkehrbare acetylierung | |
| MA27707A1 (fr) | Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme | |
| DE602007006815D1 (de) | 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxyü-piperidin-1-carbonsäure isopropyl ester als stoffwechselmodulatore und behandlung von damit assoziierten erkrankungen | |
| AU2007221366A8 (en) | Oxyntomodulin derivatives | |
| BRPI0606704A (pt) | derivados de piridinila e pirimidinila substituìdos como moduladores do metabolismo e o tratamento de distúrbios relacionados ao mesmo | |
| WO2008057856A3 (en) | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof | |
| EP2085952A4 (en) | ACTIVE MATRIX SUBSTRATE, DISPLAY SCREEN AND DISPLAY | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| BRPI0511757A (pt) | derivados de arila e heteroarila substituìdos como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a este | |
| BRPI0407620A (pt) | derivados de arila e heteroarila substituìdos como moduladores do metabolismo da glicose e a profilaxia e tratamento de seus distúrbios | |
| ATE476418T1 (de) | Benzamidderivate und assoziierte verwendungen | |
| CO6321252A2 (es) | Derivados de quinoxalindiona | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| EP2218785A3 (en) | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds | |
| CL2007002348A1 (es) | Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne. | |
| EP1774045A4 (en) | POLYGONAL NANOSTRUCTURES OF POLYNUCLEIC ACID MULTI-CORSSOVER MOLECULES AND LAYER ARRANGEMENT BASED ON DOUBLE CROSSOVER COHESION | |
| EA201000070A1 (ru) | Модуляторы калликреина 7 | |
| CY1110733T1 (el) | Κυκλικα παραγωγα ως ρυθμιστες της δραστικοτητας υποδοχεα χημειοκινων | |
| BRPI0509822A (pt) | composto sulfoniluréia pirazole, o sal do mesmo, agente agroquimico contendo o composto de sulfoniluréia pirazole e o sal do mesmo e herbicida | |
| DE602006020246D1 (de) | Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb-aktivität und deren verwendung | |
| MA32146B1 (fr) | Formulations de microcapsule de malathion stabilisees | |
| WO2005094236A3 (en) | Activation of hypoxia-inducible gene expression | |
| Ghosh et al. | Synergistic augmentation of beta-lactams: exploring quinoline-derived amphipathic small molecules as antimicrobial potentiators against methicillin-resistant Staphylococcus aureus | |
| ATE531703T1 (de) | Benzochromenderivate | |
| ATE504296T1 (de) | Zusammensetzung auf basis von rutin und l-lysin |